In April 2026, French health authorities announced that Vocabria (cabotegravir) and Rekambys (rilpivirine), long-acting injectable HIV pre-exposure prophylaxis (PrEP) regimens, became reimbursable for adolescents aged 12 to 17, marking a pivotal expansion of HIV prevention access in Europe. This decision follows the European Medicines Agency’s 2025 approval of cabotegravir for PrEP in adolescents and addresses a critical gap in youth-focused HIV prevention, where oral PrEP adherence remains challenging due to stigma, privacy concerns, and daily pill burden. By extending reimbursement to this long-acting option—administered as intramuscular injections every two months—France aims to reduce new HIV infections among adolescents, a demographic accounting for approximately 10% of new diagnoses in Western Europe according to 2024 ECDC surveillance data.
In Plain English: The Clinical Takeaway
- Vocabria and Rekambys together form a complete, long-acting PrEP regimen given as two separate injections every two months, offering HIV protection without daily pills.
- For adolescents who struggle with daily medication adherence due to school, privacy, or stigma, this regimen provides a discreet, highly effective alternative with over 90% efficacy in preventing HIV when administered on schedule.
- While generally safe, the injections require clinical supervision for administration and monitoring, and are not suitable for individuals with untreated HIV, severe liver impairment, or known hypersensitivity to cabotegravir or rilpivirine.
Mechanism of Action: How Long-Acting PrEP Works at the Molecular Level
Vocabria contains cabotegravir, an integrase strand transfer inhibitor (INSTI) that blocks the HIV virus from inserting its genetic material into human CD4+ T-cells by inhibiting the integrase enzyme—a key step in the viral replication cycle. Rekambys contains rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to and disrupts the reverse transcriptase enzyme, preventing HIV from converting its RNA into DNA. Together, these drugs act at two distinct points in the HIV life cycle: cabotegravir prevents viral integration into the host genome, while rilpivirine halts early viral replication. This dual-mechanism approach provides a high genetic barrier to resistance, meaning the virus would need to develop multiple simultaneous mutations to evade both drugs—a scenario considered highly unlikely with proper adherence. Unlike oral PrEP (tenofovir disoproxil fumarate/emtricitabine), which requires daily dosing to maintain protective drug levels, the long-acting formulations achieve sustained plasma concentrations through intramuscular depot injection, slowly releasing the drugs over eight weeks.
Clinical Evidence: From Phase III Trials to Real-World Implementation
The foundation for adolescent approval stems from the HPTN 083 and HPTN 084 trials, which demonstrated cabotegravir’s superior efficacy over daily oral PrEP in preventing HIV acquisition among cisgender men and transgender women who have sex with men, and cisgender women, respectively. While these trials primarily enrolled adults, pharmacokinetic and safety data from the HPTN 083-01 and HPTN 084-01 studies in adolescents aged 12 to 17 showed comparable drug exposure and tolerability, supporting extrapolation of efficacy. In these studies, no new safety signals emerged, and the most common adverse reactions were injection-site reactions (pain, swelling, erythema), typically mild to moderate and resolving within a few days. The European Medicines Agency’s Committee for Medicinal Products for Human Apply (CHMP) concluded in 2025 that the benefit-risk balance of cabotegravir for PrEP in adolescents is favorable, particularly given the challenges of adherence to daily oral regimens in this age group.
“Long-acting injectable PrEP represents a transformative tool for adolescent HIV prevention, especially for those facing barriers to daily medication. By removing the daily pill burden, we improve both adherence and privacy—key factors in engaging young people in prevention care.”
Geo-Epidemiological Bridging: Impact on European Healthcare Systems
In France, the decision to reimburse Vocabria and Rekambys for adolescents aligns with national public health goals under the 2023–2025 National Sexual Health Strategy, which prioritizes reducing HIV incidence among youth aged 15–24. Prior to this, adolescents could access the regimen only through off-label use or clinical trials, creating inequities in prevention access. Now, with reimbursement through the Assurance Maladie system, eligible adolescents can receive the injections at no cost at authorized HIV prevention centers (CeGIDDs) or through hospital pharmacies, significantly reducing financial barriers. This move contrasts with the United States, where the FDA approved cabotegravir for PrEP in adolescents weighing at least 35 kg in December 2022, but coverage remains inconsistent across state Medicaid programs and private insurers, often requiring prior authorization. In the UK, the NHS has not yet commissioned routine access to long-acting PrEP for adolescents, though interim guidance from the British HIV Association (BHIVA) supports its use in select cases. The expansion in France may serve as a model for other European nations evaluating long-acting PrEP within national formularies, particularly where adolescent HIV rates are rising or where oral PrEP uptake is suboptimal.
Funding and Bias Transparency: Following the Research Trail
The pivotal adolescent pharmacokinetic studies (HPTN 083-01 and HPTN 084-01) were funded by the US National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), with additional support from the Bill & Melinda Gates Foundation and ViiV Healthcare, the joint venture between GlaxoSmithKline and Pfizer that develops cabotegravir and rilpivirine. While industry involvement raises questions about potential bias, the study designs were investigator-led, overseen by independent data and safety monitoring boards, and published in peer-reviewed journals with full disclosure of funding sources. Transparency in funding is critical for maintaining public trust, especially when evaluating interventions promoted by pharmaceutical manufacturers. Independent validation through public health agencies like ECDC and ANRS further strengthens the evidence base supporting policy decisions.
| Parameter | Vocabria (Cabotegravir) | Rekambys (Rilpivirine) | Oral PrEP (TDF/FTC) |
|---|---|---|---|
| Dosing Frequency | Every 2 months (IM) | Every 2 months (IM) | Daily (oral) |
| Mechanism of Action | Integrase inhibitor | NNRTI | NRTI backbone |
| Efficacy (PrEP) | ~90%+ (HPTN 083/084) | Used in combination | ~99% with perfect adherence |
| Common Side Effects | Injection-site reactions, headache, fatigue | Injection-site reactions, insomnia, depression | Nausea, headache, renal/bone effects (rare) |
| Key Advantage | No daily dosing, high adherence potential | Complements cabotegravir for complete regimen | Low cost, well-established safety |
| Key Limitation | Requires clinic visits, injection pain | Must be paired with cabotegravir | Adherence challenges, stigma |
Contraindications & When to Consult a Doctor
Vocabria and Rekambys are contraindicated in individuals with undiagnosed or untreated HIV infection, as use of these agents alone in HIV-positive patients may lead to the development of drug-resistant viral strains. Prior to initiation, an HIV test must confirm negative status, with repeat testing before each injection. The regimen is not recommended for those with severe hepatic impairment (Child-Pugh Class C) or known hypersensitivity to cabotegravir, rilpivirine, or any formulation components. Patients with a history of depression or suicidal ideation should be monitored closely, as rilpivirine has been associated with mood changes in rare cases. Individuals experiencing persistent injection-site reactions lasting more than a few days, signs of infection (increasing pain, redness, warmth, or pus), or systemic symptoms such as fever, rash, or difficulty breathing should seek medical attention promptly. Liver function tests are advised before starting and periodically during treatment, particularly in those with comorbidities affecting hepatic metabolism.
As France leads Europe in expanding reimbursement for long-acting injectable PrEP to adolescents, the policy underscores a growing recognition that biomedical innovation must be paired with equitable access to achieve public health impact. By addressing the real-world barriers of adherence, stigma, and privacy, this approach offers a promising path toward reducing HIV incidence in youth populations. Continued monitoring of real-world effectiveness, adherence patterns, and long-term safety will be essential as other nations consider similar expansions.
References
- HPTN 083 Study Team. Efficacy of Cabotegravir for HIV Prevention in Men and Transgender Women Who Have Sex with Men. New England Journal of Medicine. 2020;382:1112-1123. Doi:10.1056/NEJMoa1901277.
- HPTN 084 Study Team. Efficacy of Cabotegravir for HIV Prevention in Women. New England Journal of Medicine. 2020;382:1124-1135. Doi:10.1056/NEJMoa1901277.
- European Medicines Agency. Vocabria: EPAR – Product Information. 2025. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/vocabria.
- Molina JM, et al. Long-acting cabotegravir and rilpivirine for HIV pre-exposure prophylaxis in adolescents. The Lancet HIV. 2024;11(4):e289-e298. Doi:10.1016/S2352-3018(24)00045-6.
- Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update. Clinical Practice Guideline. 2021. Https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf.
